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TO THE EDITOR
The acral peeling skin syndrome (APSS)
is a rare autosomal recessive condition
characterized by superficial painless
peeling of the skin predominantly on
the dorsal aspects of hands and feet
(Shwayder et al., 1997; Cassidy et al.,
2005). The condition is usually aggra-
vated by heat, humidity, and exposure
to water. Microscopically, the cleavage
level is located in the upper epidermis,
between the stratum granulosum and
the stratum corneum (Garcia et al.,
2005). Only 15 patients with APSS have
been reported since 1997 (Shwayder
et al., 1997; Brusasco et al., 1998;
Hashimoto et al., 2000; Cassidy et al.,
2005; Garcia et al., 2005; Kharfi et al.,
2009; Oumakhir et al., 2009; Wakade
et al., 2009) (Table 1). In several of
them, in addition to superficial peeling,
acral blisters were also described
(Wakade et al., 2009). The genetic
basis of the disease was determined in
only three families, in whom two
different missense mutations in the
TGM5 gene encoding transglutaminase
5 (TGase 5) were disclosed (Table 1)
(Cassidy et al., 2005; Kharfi et al.,
2009). It remains unclear whether
the other patients have mutations in
the same gene, or whether APSS is
clinically and genetically heteroge-
neous (Cassidy et al., 2005).
In this study, we investigated nine
unrelated patients, eight children and
one adult, clinically suspected to have
epidermolysis bullosa simplex (EBS)
because of acral skin blistering. The
patients and/or diagnostic samples were
referred to the Epidermolysis bullosa
Center of the University Medical Center
Freiburg (Volz et al., 2007) for mole-
cular diagnostics of EBS. EDTA-blood
and skin samples were obtained after
informed consent of the patients and, if
available, of family members. EDTA-
blood samples of 50 clinically unaf-
fected Central European individuals
were used as controls. The study was
conducted according to the Declaration
of Helsinki Principles. Immunofluores-
cence staining of skin cryosections was
performed using a panel of antibodies
to components of the epidermal base-
ment membrane zone (Kern et al.,
2006), as well as antibodies to loricrin
(Abcam, Cambridge, UK), filaggrin
(clone 15C10; Novocastra, Newcastle,
UK), involucrin (clone SY5; Sigma,
Taufkirchen, Germany), cytokeratin 10
(clone DE-K10; Dako, Glostrup,
Denmark), TGase 1 (clone B.C1; Bio-
medical Technologies, Madrid Spain),
TGase 3 (Jackson Immunoresearch
Laboratories, West Grove, PA), and
TGase 5 (Novus Biologicals, Littleton,
CO). Genomic DNA was extracted from
EDTA-blood using the QiAmp DNAmini
kit (Qiagen, Hilden, Germany). Amplifi-
cation of all KRT5 (NC_000012.11,
National Center for Biotechnology Infor-
mation (NCBI)), KRT14 (NC_000017.10,
NCBI), and TGM5 (NC_000015.9,
NCBI) exons and exon–intron bound-
aries, and sequencing were performed as
described (Schuilenga-Hut et al., 2003;
Wood et al., 2003; Cassidy et al., 2005).
Mutations were confirmed by resequen-
cing. The mutation c.763T4C was
verified in 100 control chromosomes by
Abbreviations: APSS, acral peeling skin syndrome; EBS, epidermolysis bullosa simplex; TGase,
transglutaminase
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digestion with the restriction enzyme
BsrBI according to the manufacturer’s
protocol (NEBioLabs, Ipswich, MA).
Predictions regarding the consequences
of the mutation and modeling were
performed using the software Polyphen
(http://coot.embl.de/PolyPhen/) and SWISS-
MODEL (http://swissmodel.expasy.org/
workspace/index.php?func=modelling)
(Guex and Peitsch, 1997).
The clinical phenotypes of the nine
patients in this study are summarized
in Table 1. It is noteworthy that eight
of the nine patients are children of 12
years of age or younger, with only one
adult in the cohort. Eight had had
blisters at birth or since infancy
(Figure 1a); for patient 6, no informa-
tion was available. Healing occurred
spontaneously, sometimes with residual
erythema, burning sensation, or prur-
itus, but without scarring or atrophy.
Aggravation was caused by sweating,
heat, and humidity, or by mechanical
trauma. In most cases, only the volar
and dorsal aspects of hands and feet
were affected, but in the 47-year-old
patient 4, exfoliation also occurred on
elbows and knees (Figure 1c). In older
children and in the adult patient,
peeling of the skin was the most
prominent symptom, but blisters oc-
curred occasionally. Interestingly, three
of the patients reported having a parent
(patients 5 and 9) or offspring (patient 4)
with mild features of the disease.
In the skin samples of the patients,
there were no abnormalities of the
basement membrane zone, and all
markers stained positive. This result is
compatible with the diagnosis of loca-
lized EBS, because in these patients
fragility of the skin is not prominent. In
our experience, in the biopsy samples
sent for immunofluorescence mapping
to the Epidermolysis bullosa Center
Freiburg, tissue separation is observed
only in about a third of the localized
EBS cases. Furthermore, keratin staining
is usually not altered. In some samples
in the present cohort, a discrete split in
APSS, patient 8
EBS localized
APSS, patient 4
Figure 1. Similar clinical features in APSS and localized EBS in young children. (a) Blisters (black arrows) and erosions (white arrows) on the palms and
soles of the 2-year-old patient 8 with APSS, and (b) of a 2-year-old patient with localized EBS heterozygous for the keratin 14 mutation, p.Leu143Pro. Note
the similarity of the superficial erosions and flat blisters. (c) Peeling on the dorsal aspects of the feet and discrete peeling and residual erythema on the elbows
of 47-year-old patient 4.
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the stratum corneum was present (Fig-
ure 2), suggesting the diagnosis of APSS,
which was thereafter confirmed by
mutation analysis.
Mutations in the exons and intron/
exon boundaries of the KRT5 and
KRT14 genes were excluded in all
patients. In patients 2–9, the TGM5
mutation c.337G4T, p.Gly113Cys
was disclosed in a homozygous state.
As reported before (Cassidy et al.,
2005), the mutation was associated
with the single-nucleotide polymor-
phism p.Thr109Met, also in a homo-
zygous state. The father of patient 5 and
the parents of patient 7 were hetero-
zygous carriers of the mutation and
single-nucleotide polymorphism, res-
pectively. Patient 1 was compound
heterozygous for p.Gly113Cys and for
the mutation c.763T4C, p.Trp255Arg
(Figure 2e). To our knowledge, this
mutation is previously unreported and
was excluded among 100 control chro-
mosomes by restriction digestion with
BsrBI. Tryptophan 255 is conserved in
all TGases in different species and lies
within the core domain close to the
catalytic active site of TGase 5 (see
Supplementary Figure S1 online).
The three-dimensional structure of
the core domain of the wild-type
and Trp255Arg-mutated TGase 5 was
W255 W255R
Control Patient 1
C C C C C C C C C C C C CGGGGGGGGGGGGGGGGGGG A GA A TTT A A A
Pa
tie
nt
 3
Co
nt
ro
l
Pa
tie
nt
 1
Co
nt
ro
l
TGase 5 TGase 1 TGase 3 Loricrin Filaggrin Involucrin
Figure 2. Morphological analysis of APSS skin. Immunofluorescence staining of (a) control skin from the sole, (b) skin of patient 3 from the sole, (c) control
skin from the trunk, and (d) skin of patient 1 from the trunk, with antibodies to TGase 5, TGase 1, TGase 3, loricrin, filaggrin, and involucrin. The insets
represent twofold magnifications of the marked areas. Note the altered staining of TGase 5, and the more diffuse distribution of TGase 1, loricrin, filaggrin,
and involucrin in APSS skin compared to control skin. The weak loricrin staining in the basal epidermis is likely to represent nonspecific staining. Bar¼100 mm.
(e) The TGM5 mutation c.763T4C, p.Trp255Arg. A segment of the wild-type sequence of TGM5 exon 6 is shown in the left panel, whereas the right
panel shows the heterozygous mutation c.763T4C, p.Trp255Arg found in patient 1.
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modeled using the closely related
TGase 3 as a template (PDB ID,
1I9mA; chain ID, 4) (Grenard et al.,
2001). This model revealed proximity
of amino-acid 255 to the catalytic site
of the enzyme and the conformation
changes induced by the amino-acid
substitution (Supplementary Figure S1).
Because the mutation substitutes the
large nonpolar neutral tryptophan with
the smaller, polar and positively
charged arginine, we performed a pre-
diction of electrostatic potentials using
the Poisson–Boltzmann equation. This
revealed significant differences in elec-
trostatic potentials between wild-type
(Trp255) and mutated (Arg255) core
domains (Supplementary Figure S1).
Significantly, the amino-acid stretch
Ser492–Ser501, which has been re-
cently described as an important clea-
vage region for proteolytic activation of
TGase 5 (Pietroni et al., 2008), was
strongly affected by conformation and
electrostatic changes. Therefore, we
predict that the mutation has a con-
siderable impact on TGase 5, inducing
conformation and electrostatic changes.
Compared to wild type, the mutated
TGase 5 was restricted to a few cell
layers. Similar to TGase 1 (Raghunath
et al., 1998), missense mutations may
alter activity but not enzyme expression.
In APSS skin, TGase 1 staining was dif-
fuse, but TGase 3 was not changed
(Figure 2). Kinetic and in vitro experi-
ments have indicated that TGase 5 is
very efficient in cross-linking loricrin,
involucrin, and small proline-rich pro-
teins (Candi et al., 2001). Therefore, we
investigated the effect of TGase 5 muta-
tions on the distribution of loricrin,
involucrin, and filaggrin in the skin of
five patients in vivo (1–5). Interestingly,
all three proteins were distributed in a
more diffuse manner in patients’ skin
samples compared to controls (Figure 2).
However, the molecular mechanisms
behind these findings remain to be
elucidated.
Taken together, we report that
patients with clinically suspected EBS
carried TGM5 mutations and in fact
suffered from APSS. Such an initial
assumption of epidermolysis bullosa
has been reported in literature before
(Hashimoto et al., 2000) and is under-
standable for several reasons: first, in
infants, APSS frequently manifests
with blistering on palms and soles and
is aggravated by mechanical factors
and by a humid, warm environment.
Second, in three families, a vertical
transmission of the disease was consid-
ered because either parents or offspring
were reported to have had skin blistering
in childhood. Third, similar to that
observed occasionally in localized EBS,
no tissue separation was detected by light
microscopic examination of skin biop-
sies. The superficial skin split visible in
some skin sections was considered to
be an artifact in cryosections. For these
reasons, the diagnosis of APSS was
missed. Moreover, the presumption that
APSS affects only the dorsal regions of the
hands and feet (Cassidy et al., 2005)
might have confused some clinicians. On
the basis of the above, we consider APSS
to be an important differential diagnosis
for EBS, which certainly accounts for a
number of cases in which keratin muta-
tions were not identified. Indeed, of 83
individuals referred to us with suspected
EBS, 11% had TGM5 mutations and
APSS.
Importantly, the TGM5 mutation
p.Gly113Cys was identified in nine
unrelated patients, which suggests that
it is a recurrent, possibly an ancestral,
mutation in the European population
(Cassidy et al., 2005). This finding has
practical consequences for diagnostic
testing in patients suspected to have
EBS but no keratin mutations. In such
cases, screening of the recurrent TGM5
mutation p.Gly113Cys is easy and
rapid. Finally, molecular genetics will
shed light on the different APSS pheno-
types. On the basis of the knowledge on
related skin diseases such as epidermo-
lysis bullosa, genetic and phenotypic
heterogeneity should be expected.
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Reduces UV Carcinogenesis and Nullifies Strand Bias
in p53 Mutations in Csb/ Mice
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TO THE EDITOR
Nucleotide excision repair (NER) is a
versatile repair pathway capable of
removing a wide spectrum of helix-
distorting lesions including UV light-
induced cyclobutane pyrimidine dimers
(CPDs) and 6-4 photoproducts (6-4PP)
(de Laat et al., 1999; Friedberg, 2001).
NER can operate through two subpath-
ways: global genome nucleotide exci-
sion repair (GG-NER), which removes
DNA lesions throughout the genome,
and a specialized pathway termed
transcription-coupled nucleotide exci-
sion repair (TC-NER) dedicated to the
removal of transcription-blocking lesions
within transcribed DNA (Friedberg,
2001). Genetic disorders in NER cause
three distinct human diseases: xero-
derma pigmentosum (XP), Cockayne
syndrome (CS), and trichothiodystrophy
(Lehmann, 2003; Kraemer et al., 2007;
Niedernhofer, 2008).
Mouse models have been generated
to study the impact of NER deficiencies
on cancer incidence and defects of the
immune and neurological systems
(Wijnhoven et al., 2007). The impor-
tance of NER in protecting against
UVB-induced skin cancer is manifested
by elevated cancer incidence in com-
pletely NER-deficient Xpa/, GG-NER-
deficient Xpc/, and TC-NER-deficient
Csb/ mice, thus indicating that both
NER subpathways protect from UV-
induced skin cancer (Wijnhoven et al.,
2007). In contrast, CSB patients do not
appear to be predisposed to solar
carcinogenesis. The divergence in skin
cancer susceptibility between CS pa-
tients and CS-deficient mice has been
ascribed to more efficient GG-NER in
humans than in mice, therefore redu-
cing the risk of mutagenesis in CSB
patients (van der Horst et al., 1997; van
Zeeland et al., 2005). Alternatively, or
additionally, it has been argued that the
very limited life span (o12 years) of CS
patients would not allow any manifes-
tation of increased cancer susceptibi-
lity. One way to substantiate the first
hypothesis would be to increase the
GG-NER capacity of Csb/ mice to a
level comparable to that in humans and
to subject these mice to a UV-carcino-
genic regimen.
We have recently reported that
mouse keratinocytes show higher NER
capacity than dermal fibroblasts due to
an increased level of UV-damaged
DNA-binding protein (UV-DDB) (Pines
et al., 2009). UV-DDB is essential for
GG-NER of UV-induced CPD and
accelerates repair of 6-4PP (Moser
et al., 2005). Interestingly, keratino-
cytes derived from K14-Ddb2 trans-
genic mice expressing Ddb2 from the
human K14 promoter showed en-
hanced expression of Ddb2 in the
epidermis and an NER efficiency similar
to human keratinocytes (Pines et al.,
2009).
To assess whether efficient GG-NER
is responsible for the lack of enhanced
cancer susceptibility of CSB patients,
we used WT, K14-Ddb2, K14-Ddb2/
Csb/, and Csb/ mice to investigate
UV-induced skin carcinogenesis. Mice
were exposed to a daily UV dose of
40 Jm2 and after 7 weeks of treatment
squamous cell carcinomas (SCCs) were
already detected in 25% of the Csb/
mice (Figure 1a). All Csb/ mice devel-
oped SCCs by week 17. In contrast,
more than half of the K14-Ddb2/
Csb/ mice were still tumor free after
this period of time (Figure 1a). A
significant difference between Csb/
and K14-Ddb2/Csb/ mice was also
observed in the total yield of SCCs
(Figure 1b). No tumor development was
observed at this low dose of UV
radiation (40 Jm2 UVB) in WT and
K14-Ddb2 mice. Taken together, these
results indicate that the increased GG-
NER efficiency in mouse epidermal
Abbreviations: CPD, cyclobutane pyrimidine dimer; GG, global genome; NER, nucleotide excision
repair; SCC, squamous cell carcinoma; XP, xeroderma pigmentosum
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